Funding rounds: Desentum, River BioMedics, Smarter Health, Healthcare At Home India, Shanghai ZhenGe Biotech

China: Shanghai ZhenGe Biotech, a one-stop CDMO with expertise across monoclonal and bispecific antibodies, Antibody Drug Conjugates (ADC), fusion proteins and vaccines, has completed a round C financing of US$100m. The round was led by Goldman Sachs Asset Management (GSAM) and Sofina. Also investing were Novo Holdings, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital…

You must be a HMI Subscriber to view this content.

Subscribe Now »